Abstract：
OBJECTIVE: The aim of this study was to evaluate if the previously reported improvements in lung cancer survival were consistent across age at diagnosis and by lung cancer subtypes.
METHODS: Data on lung cancers diagnosed between 1990 and 2016 in Denmark, Finland, Iceland, Norway and Sweden were obtained from the NORDCAN database. Flexible parametric models were used to estimate age-standardized and age-specific relative survival by sex, as well as reference-adjusted crude probabilities of death and life-years lost. Age-standardised survival was also estimated by the three major subtypes; adenocarcincoma, squamous cell and small-cell carcinoma.
RESULTS: Both 1- and 5-year relative survival improved continuously in all countries. The pattern of improvement was similar across age groups and by subtype. The largest improvements in survival were seen in Denmark, while improvements were comparatively smaller in Finland. In the most recent period, age-standardised estimates of 5-year relative survival ranged from 13% to 26% and the 5-year crude probability of death due to lung cancer ranged from 73% to 85%. Across all Nordic countries, survival decreased with age, and was lower in men and for small-cell carcinoma.
CONCLUSIONS: Lung cancer survival has improved substantially since 1990, in both women and men and across age. The improvements were seen in all major subtypes. However, lung cancer survival remains poor, with three out of four patients dying from their lung cancer within five years of diagnosis.
METHODS: Data on lung cancers diagnosed between 1990 and 2016 in Denmark, Finland, Iceland, Norway and Sweden were obtained from the NORDCAN database. Flexible parametric models were used to estimate age-standardized and age-specific relative survival by sex, as well as reference-adjusted crude probabilities of death and life-years lost. Age-standardised survival was also estimated by the three major subtypes; adenocarcincoma, squamous cell and small-cell carcinoma.
RESULTS: Both 1- and 5-year relative survival improved continuously in all countries. The pattern of improvement was similar across age groups and by subtype. The largest improvements in survival were seen in Denmark, while improvements were comparatively smaller in Finland. In the most recent period, age-standardised estimates of 5-year relative survival ranged from 13% to 26% and the 5-year crude probability of death due to lung cancer ranged from 73% to 85%. Across all Nordic countries, survival decreased with age, and was lower in men and for small-cell carcinoma.
CONCLUSIONS: Lung cancer survival has improved substantially since 1990, in both women and men and across age. The improvements were seen in all major subtypes. However, lung cancer survival remains poor, with three out of four patients dying from their lung cancer within five years of diagnosis.
摘要：
目的：本研究的目的是评估以前报道的肺癌生存率的改善是否在诊断年龄和肺癌亚型之间一致。
方法：1990年至2016年丹麦肺癌诊断数据，芬兰,冰岛,挪威和瑞典是从NORDCAN数据库获得的。灵活的参数模型用于按性别估计年龄标准化和特定年龄的相对生存率，以及参考调整后的死亡和寿命损失的粗略概率。年龄标准化生存率也由三个主要亚型估计;腺癌,鳞状细胞癌和小细胞癌。
结果：所有国家的1年和5年相对生存率均持续改善。不同年龄组和不同亚型的改善模式相似。生存率的最大改善发生在丹麦，而芬兰的改善相对较小。在最近的时期,年龄标准化的5年相对生存率估计值为13%~26%,5年肺癌死亡的粗概率为73%~85%.在所有北欧国家，存活率随着年龄的增长而下降，在男性和小细胞癌中较低。
结论：自1990年以来，女性和男性以及不同年龄的肺癌生存率均有显著提高。在所有主要亚型中都看到了改善。然而,肺癌生存率仍然很低，四分之三的患者在诊断后的五年内死于肺癌。
方法：1990年至2016年丹麦肺癌诊断数据，芬兰,冰岛,挪威和瑞典是从NORDCAN数据库获得的。灵活的参数模型用于按性别估计年龄标准化和特定年龄的相对生存率，以及参考调整后的死亡和寿命损失的粗略概率。年龄标准化生存率也由三个主要亚型估计;腺癌,鳞状细胞癌和小细胞癌。
结果：所有国家的1年和5年相对生存率均持续改善。不同年龄组和不同亚型的改善模式相似。生存率的最大改善发生在丹麦，而芬兰的改善相对较小。在最近的时期,年龄标准化的5年相对生存率估计值为13%~26%,5年肺癌死亡的粗概率为73%~85%.在所有北欧国家，存活率随着年龄的增长而下降，在男性和小细胞癌中较低。
结论：自1990年以来，女性和男性以及不同年龄的肺癌生存率均有显著提高。在所有主要亚型中都看到了改善。然而,肺癌生存率仍然很低，四分之三的患者在诊断后的五年内死于肺癌。
